Used in the treatment of relapsed or refractory multiple myeloma, this antibody targets BCMA on malignant plasma cells, enabling immune-mediated destruction through mechanisms like antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. It serves as a critical component in monoclonal antibody therapy for patients who have exhausted other treatment options.